MK-677 vs GH peptides: how they really compare

“Is MK-677 just an oral version of a growth-hormone peptide?” is a fair question, and the honest answer changes how you should think about both. MK-677 (ibutamoren) and injectable GH peptides such as CJC-1295 and ipamorelin do aim at the same target, nudging the body to release more of its own growth hormone (GH) and, downstream, insulin-like growth factor 1 (IGF-1), but they are different molecules, taken different ways, with different side-effect profiles. This page compares them on the things that actually decide a good decision: what each one is, how the mechanisms differ, how strong the human evidence really is, and what side effects each carries. It leans on primary clinical sources rather than vendor copy, and it does not promote the non-medical use of either. For the underlying pharmacology of the injectable side, see our companion explainer on what CJC-1295 and ipamorelin actually do.

Is MK-677 a peptide?

No, and that is the single most important thing to get straight before comparing it to GH peptides. MK-677, also called ibutamoren, is an orally active, non-peptide small molecule that mimics ghrelin, the hormone that switches on growth-hormone release. The Uniformed Services University’s Operation Supplement Safety program, a Department of Defense resource, describes it plainly and notes it “is not approved for human use, which makes it an unapproved drug,” per the OPSS overview of MK-677. Injectable GH peptides are the opposite in structure: they are actual peptides, short chains of amino acids. In the peer-reviewed literature ipamorelin is defined as “a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency,” in the study by Raun and colleagues, and CJC-1295 is “a long-acting analog of GH-releasing hormone.” So MK-677 is best understood as an oral GH secretagogue that is chemically not a peptide at all, while CJC-1295 and ipamorelin are injectable peptides. Marketing that calls MK-677 an “oral peptide” is wrong on the chemistry.

How do their mechanisms differ?

Both routes end at more GH and IGF-1, but they arrive by different receptors and, critically, by different delivery. MK-677 works orally by imitating ghrelin at the growth-hormone-secretagogue receptor, which is why an early trial calls it “the oral growth hormone (GH) secretagogue MK-677” in the obesity study by Svensson and colleagues. Ipamorelin acts at the same ghrelin-type receptor but must be injected; Raun’s group reported it “stimulates GH release via a GHRP-like receptor” and, notably, “did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation.” CJC-1295 pushes on the parallel GHRH pathway: in the human pharmacology trial by Teichman and colleagues, a single injection produced “dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d.” The practical differences that follow are real: MK-677 is a daily oral tablet with a long enough action to raise GH around the clock, whereas the peptides are injectables. That around-the-clock oral elevation is also why MK-677’s side-effect profile, appetite, fluid retention, blood sugar, shows up the way it does, covered below.

Does MK-677 have more evidence than GH peptides?

Surprisingly, yes, MK-677 has been studied in humans more thoroughly than most injectable GH peptides, and that larger evidence base is exactly why it is worth reading carefully rather than hopefully. The most informative trial is a two-year, double-blind, randomized, placebo-controlled study in 65 healthy older adults, published in the Annals of Internal Medicine by Nass and colleagues. Daily oral MK-677 did increase fat-free mass, up 1.1 kg versus a 0.5 kg loss on placebo, but the authors are blunt about what that did not translate into: “Increased FFM did not result in changes in strength or function.” Shorter studies show the same anabolic signal on the scale without a proven functional payoff. In Svensson’s 8-week study of obese men, “serum insulin-like growth factor I (IGF-I) increased approximately 40%” and “fat-free mass increased significantly,” and in a caloric-restriction study, Murphy and colleagues found “MK-677 reverses diet-induced nitrogen wasting.” That is a genuinely more developed record than CJC-1295 or ipamorelin, whose human data is thinner and, for physique specifically, essentially absent. But “more evidence” cuts the other way here: the better-studied compound is the one whose best trial explicitly failed to show a strength or function benefit. More data did not mean a better result, it meant a clearer null. PeptideAgent’s ipamorelin vs MK-677 comparison draws the same contrast, setting MK-677’s years of randomized data against ipamorelin’s single negative trial.

MK-677 vs GH peptides, side by side

Side by side, MK-677 and the injectable GH peptides differ in structure, delivery, and how much human data exists, but they converge on the limitation that matters most for anyone chasing physique goals: neither has a body of evidence showing a real functional benefit. The table maps what each one is, how it is taken, mechanism, the human evidence, FDA approval, anti-doping status, and documented safety concerns. Read it as a risk map, not a scoreboard, there is deliberately no “winner” row, because neither column earns one.

MK-677 (ibutamoren) vs injectable growth-hormone peptides (CJC-1295, ipamorelin), on the dimensions that decide how much weight to give either one. Evidence and mechanism reflect the cited clinical literature; anti-doping facts are sourced below.

Attribute	MK-677 (ibutamoren)	GH peptides (CJC-1295, ipamorelin)
What it is	An orally active, non-peptide ghrelin mimetic	Injectable peptides (a GHRH analog and a GH secretagogue)
Is it a peptide	No	Yes
How it is taken	Oral tablet, once daily	Subcutaneous injection
Primary mechanism	Mimics ghrelin at the GH-secretagogue receptor to raise GH/IGF-1	Stimulate pituitary GH release (GHRH analog / GH secretagogue)
Human trial evidence exists	Yes	Yes
What the human data actually shows	Raised fat-free mass but no strength/function gain; raised fasting glucose	Short studies of raised GH/IGF-1; no body-composition trials
Proven physique/strength benefit in trials	No	No
Approved by the FDA for any use	No	No
Anti-doping status (WADA)	Prohibited at all times (S2, GH secretagogues)	Prohibited at all times (S2, GH secretagogues / releasing factors)
Documented safety concerns	Higher fasting glucose, lower insulin sensitivity, appetite, edema, raised cortisol	Long-term safety in this use never established

What side effects does MK-677 cause?

MK-677’s side effects are well described because it was studied for two years, and they follow from raising growth hormone around the clock: more appetite, fluid, and higher blood sugar. In the two-year trial in healthy adults aged 60 to 81, the most frequent side effects were “an increase in appetite that subsided in a few months and transient, mild lower-extremity edema and muscle pain.” Fasting blood glucose rose by an average of 5 mg/dL, insulin sensitivity decreased, cortisol rose, and body weight went up 2.7 kg versus 0.8 kg on placebo, while the authors still described the drug as generally well tolerated (Nass et al., 2008). The Defense Department’s Operation Supplement Safety program adds a caution about potential “congestive heart failure in certain patients,” alongside effects on blood glucose and bone (OPSS).

For a lifter, the appetite effect deserves particular attention, since more hunger makes a calorie deficit harder to hold. The blood-sugar signal is worth knowing about for anyone already watching their glucose, because the trial measured it in healthy people and it still moved in the wrong direction. The injectable peptides have far less safety data: the CJC-1295 trials ran weeks rather than years (Teichman et al., 2006), so their long-term side-effect profile is simply unknown rather than known to be better.

Are MK-677 and GH peptides allowed in sport?

No, both are banned. The World Anti-Doping Agency prohibits growth-hormone secretagogues at all times, in and out of competition, under category S2 of the WADA Prohibited List. MK-677 falls in that section as a GH secretagogue, and so do CJC-1295 and ipamorelin as growth-hormone-releasing factors and secretagogues. The OPSS resource adds that MK-677 is on both the WADA Prohibited List and the DoD Prohibited Dietary Supplement Ingredients List. Any athlete tested by WADA, USADA, the NCAA, the military, or a WADA-compliant body cannot use either without risking a sanction, and a “research use only” or “supplement” label changes none of it.

Is MK-677 or a GH peptide the better choice for building muscle?

The honest answer is that neither is a proven muscle-building drug, so the better choice is not one of these two columns, it is a plan built with a licensed provider who can check your labs. MK-677’s best evidence is a cautionary tale for physique users: it raised fat-free mass but, in the words of the two-year trial, that increase “did not result in changes in strength or function,” while the same study documented higher fasting glucose, reduced insulin sensitivity, transient edema, and increased cortisol. The GH peptides have less human data and, for physique specifically, essentially none. So the real decision most people face is not “MK-677 versus GH peptide”, it is “an unmonitored compound with known metabolic downsides or unknown long-term effects versus a plan built around what actually has evidence.” A provider can weigh your goal, order appropriate labs, and talk through monitored options that may look nothing like the compound in the headline. If your aim is muscle, recovery, or body composition, bring that goal, not a product name, to someone who can weigh it responsibly. Our explainer on what CJC-1295 and ipamorelin actually do and the honest comparison of GH peptides and anabolic steroids turn everything here into questions you can actually ask, and the checklist below does the same.

Status: MK-677 is not approved for human use (OPSS). CJC-1295 and ipamorelin: Not FDA-approved; sold by some telehealth providers as a compounded prescription. What this status means.

Educational information only, not medical advice, and not an endorsement of non-medical use of either compound. Every statement on this page is sourced to the peer-reviewed, WADA and DoD/OPSS documents linked above. Updated October 12, 2026.